Connect with us

health

NCDC reports 674 Lassa fever cases, 127 deaths in early 2025

The NCDC has confirmed 674 Lassa fever cases and 127 deaths across 18 states in Nigeria from January to April 6, 2025.

Published

on

Nigeria Lassa Fever Outbreak 2025

The NCDC has confirmed 674 Lassa fever cases and 127 deaths across 18 states in Nigeria from January to April 6, 2025

 

adron lemon friday

The Nigeria Centre for Disease Control and Prevention (NCDC) has reported a total of 674 confirmed cases of Lassa fever, with 127 associated deaths, across 18 states and 93 local government areas in Nigeria between January and April 6, 2025.

Also read: First lady Oluremi Tinubu advocates for maternal, newborn health on World Health Day 2025

This information was released in the NCDC’s latest situation report on Tuesday. The Case Fatality Rate (CFR) currently stands at 18.8 per cent.

The states that have recorded fatalities include Ondo (26), Bauchi (12), Edo (17), Taraba (31), Ebonyi (11), Kogi (four), Plateau (five), Gombe (seven), Benue (four), Nasarawa (four), Kaduna (two), Enugu (one), Delta (one), Cross-River (one), and Ogun (one).

Lassa fever is an acute viral haemorrhagic fever caused by the Lassa virus, with the multimammate rat being the primary natural reservoir.

The NCDC report highlighted that in the 14th week of 2025, 15 new confirmed cases were recorded, an increase from the 14 cases reported in the previous week.

These new cases were identified in Ondo, Bauchi, Edo, Taraba, Ebonyi, and Gombe States. Cumulatively, by week 14, the 127 deaths reported resulted in a CFR of 18.8 per cent, which is slightly higher than the 18.5 per cent CFR recorded during the same period in 2024.

The majority (71 per cent) of all confirmed Lassa fever cases in 2025 have been reported from three states: Ondo (30 per cent), Bauchi (25 per cent), and Edo (16 per cent).

The remaining 28 per cent of cases were reported from the other 15 affected states. The most affected age group is between 21 and 30 years, with an overall age range of 1 to 94 years and a median age of 30 years. The male-to-female ratio among confirmed cases is 1:0.8.

The NCDC noted a decrease in the number of suspected cases compared to the same period in 2024, and no new healthcare workers were affected in week 14. The National Lassa fever multi-partner, multi-sectoral Incident Management System has been activated to coordinate response efforts at all levels.

5 / 100 SEO Score

health

FCCPC Moves Against Producers Over Poorly Fortified Oil, Salt

Published

on

FCCPC orders producers to comply with food fortification standards after a survey found inadequately fortified vegetable oil and salt in Nigerian markets

(more…)

adron lemon friday

68 / 100 SEO Score
Continue Reading

health

UK Tests Five-Day Breast Cancer Radiotherapy in Major Trial

Published

on

The UK is testing five-day breast cancer radiotherapy in a major trial that could reduce hospital visits and treatment costs for patients

The United Kingdom has launched a major clinical trial involving more than 1,000 participants to determine whether breast cancer radiotherapy can be shortened from three weeks to five days without compromising its effectiveness in preventing the disease from returning.

Also read: Grey CEO Urges Africa to Ditch Dollar for Trade

adron lemon friday

The government-funded FAST-Forward Boost trial, being conducted at 39 hospitals across the UK, will investigate whether a shorter course of radiotherapy combined with an additional targeted dose, known as a boost, can provide effective treatment for patients following breast cancer surgery.

The UK Department of Health and Social Care announced the development on Friday, October 30, describing the study as part of efforts to improve cancer treatment and make care more convenient for patients.

Led by the Institute of Cancer Research in London and funded by the National Institute for Health and Care Research, the study aims to recruit 4,830 participants by 2028.

Those enrolled will be followed up for five years, with results expected in 2033.

If the approach proves successful, it could reduce the number of hospital visits required by patients, potentially saving them 10 journeys compared with the existing three-week treatment schedule.

The department said the shorter schedule could also reduce transport expenses and the time patients spend away from work and family.

It could additionally ease pressure on the National Health Service by freeing up radiotherapy capacity for other patients.

Health and Social Care Secretary Yvette Cooper said the trial reflected the country’s efforts to use medical research to improve cancer care.

“This trial shows how the UK is using our world beating research capabilities to pursue huge improvements and transformations in cancer treatment for patients,” she said.

Why the radiotherapy trial matters

Radiotherapy uses carefully targeted radiation to destroy cancer cells or prevent them from growing.

For many people with breast cancer, it is recommended after surgery to reduce the risk of the disease returning in the treated area.

A treatment boost involves delivering an additional dose of radiation to the area considered to have a higher risk of recurrence, usually the site where the tumour was removed.

The FAST-Forward Boost trial is examining how this additional treatment can be incorporated into a shorter schedule.

Reducing treatment from three weeks to five days could make a considerable difference to patients who must travel regularly to hospitals.

The impact may be particularly significant for people living far from specialist cancer centres, those with limited transport options and patients balancing treatment with employment or family responsibilities.

However, the trial is designed to establish whether the shorter approach is effective and safe for the patients being studied. Its results will be important in determining whether the treatment schedule can become a wider option in clinical practice.

UK expands breast cancer screening efforts

The announcement comes as the British government intensifies efforts to improve breast cancer screening, encourage early diagnosis and strengthen support for patients.

The Department of Health and Social Care said screening uptake among women receiving their first invitation had risen to 63.6 per cent, its highest level in a decade.

Despite the improvement, around four in 10 women invited for their first screening appointment still do not attend.

The government is also working with the National Institute for Health and Care Research and NHS England on studies examining how artificial intelligence could support the analysis of mammograms.

The technology is being explored as a way to assist the assessment of breast screening images, although its role and effectiveness must be established through appropriate research and clinical evaluation.

In addition, the government has partnered with breast cancer charity Breast Cancer Now for three years to help women recognise symptoms, find reliable information and access support after treatment.

Together, the initiatives reflect a broader approach to breast cancer care, combining screening, research into treatment improvements and support for people living with the disease.

Also read: Grey CEO Urges Africa to Ditch Dollar for Trade

For now, the five-day radiotherapy approach remains under investigation. With final results not expected until 2033, the FAST-Forward Boost trial will need to establish whether reducing treatment time can deliver comparable cancer control while maintaining patient safety.

65 / 100 SEO Score
Continue Reading

health

DR Congo Faces Deadly Ebola Surge, WHO Warns

Published

on

The DR Congo Ebola outbreak is recording 50 to 80 new confirmed cases daily, with about 10,000 cases and nearly 5,000 deaths reported

(more…)

adron lemon friday

57 / 100 SEO Score
Continue Reading

Trending News